Clinomics Europe has joined the European Liquid Biopsy Society (ELBS)
We are thrilled to announce that Clinomics Europe has joined the European Liquid Biopsy Society (ELBS)! As one of over 70 partners from academia and industry, Clinomics Europe is now part of a dynamic network working towards the common goal of bringing liquid biopsy tests into clinical routine.
The ELBS network covers all relevant areas needed to achieve this goal, including harmonization of technologies, clinical study design, and interaction with regulatory bodies. By combining the collective expertise and knowledge of its members with the strategic implementation of joint projects, the ELBS is uniquely positioned to drive progress in the field of liquid biopsy.
We are excited to be part of this impressive network, and look forward to working alongside other ELBS members to advance this promising field!
Recent blogs
Liquid biopsy in HPV-associated cervical cancer
Cervical cancer and HPV Cervical cancer is one of the most frequently diagnosed cancer types in women worldwide. According to 2020 statistics, it is the fourth leading cause of cancer death [1],...
Single-Cell Multi-omics of Circulating Tumor Cells
As oncology analytical approaches are continuously developing, cancer can be understood in deeper and more detailed ways. However, we still struggle to capture potentially important subpopulations...
Cell-free DNA and circulating tumor cells: which has more potential in precision oncology?
Many studies have demonstrated the advantages of technologies based on liquid biopsy in the genomic profiling of cancer patients. Blood-derived cell-free DNA (cfDNA)- and circulating tumor cell...